My doctor was of the opinion that over-medicalisation of patients was a common problem, and that a high PSA reading might ...
A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...
Swiss drugmaker Novartis said on Sunday its targeted radiotherapy treatment Pluvicto reduced the risk of progression or death ...